 ROCKVILLE, MD, Nov. 02, 2022 GLOBE NEWSWIRE -- MacroGenics, Inc. Nasdaq: MGNX, a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Companys management will participate in the following investor conferences in November 2022. 